VNDA
Vanda Pharmaceuticals Inc
5.10$
+1.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 82.5% | 78.2% | 82.8% | 82.7% | 90.1% | 73.2% | 76.7% | 80.6% | 81.9% | 66.8% | 66.9% | 71.0% | |
| 35.5% | 23.9% | 19.2% | 16.4% | 18.4% | 9.3% | 11.4% | 8.8% | 21.3% | 20.9% | 15.6% | 17.4% | |
| 75.6% | 67.2% | 67.2% | 69.8% | 77.5% | 64.5% | 68.9% | 72.9% | 73.6% | 59.9% | 57.1% | 54.0% | |
| 2.1% | 7.7% | 9.6% | 8.6% | 8.7% | 5.5% | 5.6% | 5.5% | 5.3% | 5.3% | 7.2% | 11.2% | |
| 3.0% | 0.6% | 0.4% | 0.4% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% | 0.4% | |
| 1.4% | 2.1% | 2.4% | 2.6% | 1.3% | 0.8% | 0.8% | 2.1% | 0.4% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 15.6% | 18.2% | 13.2% | 12.7% | 7.4% | 4.8% | 4.0% | 3.4% | 2.9% | 18.7% | 17.4% | 23.9% | |
| 6.3% | 37.6% | 37.6% | 36.0% | 17.1% | 15.0% | 15.0% | 15.0% | 16.9% | 16.0% | 17.9% | 33.1% | |
| 4.5% | 24.1% | 23.9% | 34.3% | 16.0% | 12.3% | 12.4% | 12.5% | 14.4% | 13.5% | 15.2% | 29.7% | |
| 3.9% | – | – | 13.1% | – | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.7% | 1.1% | |
| 0.5% | 1.7% | 1.6% | 9.9% | 1.1% | 1.2% | 0.2% | 0.2% | 2.0% | 1.1% | 0.5% | 1.0% | |
| 0.0% | 11.7% | 11.9% | 0.0% | – | – | – | – | – | – | – | – | |
| 93.7% | 62.4% | 62.4% | 64.0% | 82.9% | 85.0% | 85.0% | 85.0% | 83.1% | 84.0% | 82.1% | 66.9% | |
| -167.7% | -153.9% | -164.4% | -175.9% | -101.2% | -45.6% | -37.0% | -27.6% | -24.9% | -24.0% | -26.6% | -80.7% | |
| 21.4% | 19.8% | 20.7% | 21.8% | 16.0% | 11.3% | 10.3% | 9.6% | 9.0% | 8.9% | 8.9% | 12.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.